Title: Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting
Authors: Kleintjens, Joris ×
Li, Xiaochen
Simoens, Steven
Thijs, Vincent
Goethals, Marnix
Rietzschel, Ernst R
Asukai, Yumi
Saka, Ömer
Evers, Thomas
Faes, Petra
Vansieleghem, Stefaan
De Ruyck, Mimi #
Issue Date: Oct-2013
Publisher: Adis International
Series Title: Pharmacoeconomics vol:31 issue:10 pages:909-18
Pharmacoeconomics vol:31 issue:10 pages:909-918
Article number: 10.1007/s40273-013-0087-9
Abstract: Warfarin, an inexpensive drug that has been available for over half a century, has been the mainstay of anticoagulant therapy for stroke prevention in patients with atrial fibrillation (AF). Recently, rivaroxaban, a novel oral anticoagulant (NOAC) which offers some distinct advantages over warfarin, the standard of care in a world without NOACs, has been introduced and is now recommended by international guidelines.
ISSN: 1170-7690
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory for Neurobiology
Clinical Pharmacology and Pharmacotherapy
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science